Alfred L. Garfall, MD, MS

Alfred L. Garfall, MD, MS, is an associate professor of medicine (hematology-oncology) and director of the Autologous Hematopoietic Cell Transplantation, Cell Therapy and Transplant Program at Hospital of the University of Pennsylvania. He is also section chief of Multiple Myeloma in the Division of Hematology/Oncology, in the Department of Medicine, at Perelman School of Medicine, of University of Pennsylvania.

Articles

Dr Garfall on the Rationale of the Phase 2 BMT CTN 1902 Trial in Myeloma

April 21st 2025

Alfred L. Garfall, MD, MS, discusses the rationale of the phase 2 BMT CTN 1902 trial in multiple myeloma.

Dr Garfall on the Inclusion Criteria for a Study Evaluating Ide-Cel in Myeloma After Suboptimal Transplant/Maintenance Response

March 19th 2025

Alfred L. Garfall, MD, describes the inclusion criteria for a phase 2 study evaluating ide-cel as first-line maintenance in multiple myeloma.

Dr Garfall on the Potential Role for Consolidation or Maintenance CAR T-Cell Therapy in Myeloma

March 5th 2025

Alfred Garfall, MD, discusses the potential role of CAR T-cell therapy in multiple myeloma either as consolidation or maintenance in the up-front setting.

Dr Garfall on Ide-Cel and Lenalidomide Maintenance in Myeloma After Suboptimal ASCT Response

February 17th 2025

Alfred L. Garfall, MD, MS, discusses data for ide-cel and lenalidomide maintenance in multiple myeloma following a suboptimal response to ASCT and lenalidomide.

Dr Garfall on Updated Safety Data for Teclistamab in R/R Myeloma

July 18th 2024

Alfred L. Garfall, MD, MS, discusses updated safety data for teclistamab in relapsed/refractory multiple myeloma.

Dr Garfall on Long-Term Data for Teclistamab in Relapsed/Refractory Myeloma

July 11th 2024

Alfred L. Garfall, MD, MS discusses updated long-term data for teclistamab in patients with relapsed/refractory multiple myeloma.

Dr. Garfall Discusses CAR T-Cell Therapy in Multiple Myeloma

November 22nd 2019

Alfred L. Garfall, MD, MS, discusses the potential of CAR T-cell therapy in multiple myeloma.

Dr. Garfall on Impact of CAR T-Cell Therapy in Hematologic Malignancies

March 22nd 2017

Alfred L. Garfall, MD, MS, assistant professor of Medicine, the Hospital of the University of Pennsylvania, discusses the impact of chimeric antigen receptor (CAR) T-cell therapy in hematologic malignancies.

Dr. Garfall on CAR T Cells in ALL

February 28th 2017

Alfred L. Garfall, MD, MS, assistant professor of Medicine at the Hospital of the University of Pennsylvania, discusses CAR T-cells in acute lymphoblastic leukemia (ALL).